affymetrix, bangs & merck deals, page-4

I believe ds is quite right about the problem with Bangs' marketing; I gather another issue has been that Bangs has not been comfortable with Anteo's move into direct sales - Anteo is perhaps seen as a competitor.

Concerning Affymetrix, I don't know how well current sales have been going, but we do know that Mix&Go is in many of their products now, so indirect sales of Mix&Go must be happening, I imagine. But one would need to check with Anteo about the current progress in sales, and there may be commercial reasons for not disclosing that information, e.g. Affymetrix not approving releasse of such figures, protecting their own patch.

I agree, oslo, I like the direct sales, particularly as it means that Mix&Go can get out to those in R&D so they can see for themselves just what difference it does make. It's a very interesting stage for the company, one of those great inflexion points, as a number of initiatives start coming together - POC projects, early direct sales, possible Chinese IVD beads, Luminex (?), and now perhaps a couple of big pharmas (eg Roche etc).

Meanwhile, further work on low-level patents can continue, and it will be from this work that an outstanding financial future for the company and its shareholders will emerge.